• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MHC II类分子限制的抗原呈递

MHC class II restricted antigen presentation.

作者信息

Pieters J

机构信息

Basel Institute for Immunology, Grenzacherstrasse 487, Postfach CH-4005 Basel, Switzerland.

出版信息

Curr Opin Immunol. 1997 Feb;9(1):89-96. doi: 10.1016/s0952-7915(97)80164-1.

DOI:10.1016/s0952-7915(97)80164-1
PMID:9039772
Abstract

Presentation of antigenic peptides by MHC class II molecules to CD4(+) T cells requires many events in both the biosynthetic and endocytic pathways that must all occur in a controlled and coordinated fashion. In recent years the roles of two important chaperones, the invariant chain and the HLA-DM dimer, in promoting the acquisition of peptides by MHC class II molecules have largely been elucidated. The different compartments within the endosomal/lysosomal pathway that are involved in peptide loading are now being characterized. In addition to the specialized MHC class II compartments that exist in antigen-presenting cells, other intracellular compartments may also be involved in peptide loading. The precise mechanisms and intracellular sites of MHC class II peptide loading appear to dictate the nature of the T-cell epitopes presented by the antigen-presenting cell.

摘要

MHC II类分子将抗原肽呈递给CD4(+) T细胞需要生物合成途径和内吞途径中的许多事件,这些事件都必须以可控且协调的方式发生。近年来,两种重要的伴侣蛋白——恒定链和HLA-DM二聚体,在促进MHC II类分子获取肽段方面的作用已基本阐明。参与肽段装载的内体/溶酶体途径中的不同区室目前正在被表征。除了抗原呈递细胞中存在的专门的MHC II类区室外,其他细胞内区室也可能参与肽段装载。MHC II类分子肽段装载的精确机制和细胞内位点似乎决定了抗原呈递细胞所呈递的T细胞表位的性质。

相似文献

1
MHC class II restricted antigen presentation.MHC II类分子限制的抗原呈递
Curr Opin Immunol. 1997 Feb;9(1):89-96. doi: 10.1016/s0952-7915(97)80164-1.
2
Antigen presentation by MHC class II molecules.MHC II类分子介导的抗原呈递
Immunol Cell Biol. 1997 Feb;75(1):69-81. doi: 10.1038/icb.1997.11.
3
HLA-DM and the MHC class II antigen presentation pathway.HLA-DM与MHC II类抗原呈递途径。
Immunol Res. 1999;20(3):195-205. doi: 10.1007/BF02790403.
4
Analysis of subcellular organelles involved in major histocompatibility complex (MHC) class II-restricted antigen presentation by electrophoresis.通过电泳分析参与主要组织相容性复合体(MHC)II类限制性抗原呈递的亚细胞器。
Electrophoresis. 1997 Dec;18(14):2523-30. doi: 10.1002/elps.1150181406.
5
Distinct intracellular compartments involved in invariant chain degradation and antigenic peptide loading of major histocompatibility complex (MHC) class II molecules.参与主要组织相容性复合体(MHC)II类分子恒定链降解和抗原肽加载的不同细胞内区室。
J Cell Biol. 1997 Dec 15;139(6):1433-46. doi: 10.1083/jcb.139.6.1433.
6
Trafficking of major histocompatibility complex class II molecules through intracellular compartments containing HLA-DM.主要组织相容性复合体II类分子通过含有HLA-DM的细胞内区室的转运。
Hum Immunol. 1996 Jan;45(1):13-23. doi: 10.1016/0198-8859(95)00152-2.
7
DM and DO shape the repertoire of peptide-MHC-class-II complexes.树突状细胞(DC)和专职抗原呈递细胞(pAPC)塑造了肽 - 主要组织相容性复合体II类(peptide-MHC-class-II)复合物的库。 (注:原文中DM和DO有误,正确的应该是DC和pAPC,已按照正确内容翻译)
Curr Opin Immunol. 2005 Feb;17(1):65-70. doi: 10.1016/j.coi.2004.11.003.
8
Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression.通过编辑和陪伴实现稳定性:MHC II类分子肽结合与表达的调控
Immunol Rev. 2005 Oct;207:242-60. doi: 10.1111/j.0105-2896.2005.00306.x.
9
The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells.MHC II类相关恒定链:一种在MHC II类生物合成及向CD4+ T细胞呈递抗原过程中发挥多种作用的分子。
Crit Rev Immunol. 1996;16(4):359-79.
10
The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells.CLIP替代的恒定链可有效地将抗原肽靶向L细胞中的HLA II类途径。
Hum Immunol. 1998 Oct;59(10):607-14. doi: 10.1016/s0198-8859(98)00058-5.

引用本文的文献

1
Transcriptome Profiling of the Retained Fetal Membranes-An Insight in the Possible Pathogenesis of the Disease.留存胎膜的转录组分析——对该疾病可能发病机制的深入了解
Animals (Basel). 2021 Mar 3;11(3):675. doi: 10.3390/ani11030675.
2
Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients.人类白细胞抗原系统作为癌症患者基于检查点免疫治疗的预测性生物标志物的作用。
Int J Mol Sci. 2020 Oct 2;21(19):7295. doi: 10.3390/ijms21197295.
3
Exopolysaccharide Produced by Lactobacillus Plantarum Induces Maturation of Dendritic Cells in BALB/c Mice.
植物乳杆菌产生的胞外多糖诱导BALB/c小鼠树突状细胞成熟。
PLoS One. 2015 Nov 24;10(11):e0143743. doi: 10.1371/journal.pone.0143743. eCollection 2015.
4
Role of individual's T-cell immunome in controlling HIV-1 progression.个体T细胞免疫组在控制HIV-1病情进展中的作用。
Immunology. 2014 Dec;143(4):631-9. doi: 10.1111/imm.12344.
5
Mycobacterium tuberculosis: success through dormancy.结核分枝杆菌:休眠中的成功之道。
FEMS Microbiol Rev. 2012 May;36(3):514-32. doi: 10.1111/j.1574-6976.2012.00331.x. Epub 2012 Mar 8.
6
Immunomodulatory properties of a viral homolog of human interleukin-10 expressed by human cytomegalovirus during the latent phase of infection.人巨细胞病毒在潜伏感染期表达的人白细胞介素-10病毒同源物的免疫调节特性。
J Virol. 2008 Apr;82(7):3736-50. doi: 10.1128/JVI.02173-07. Epub 2008 Jan 23.
7
Herpesvirus interference with major histocompatibility complex class II-restricted T-cell activation.疱疹病毒对主要组织相容性复合体II类限制性T细胞活化的干扰。
J Virol. 2007 May;81(9):4389-96. doi: 10.1128/JVI.01525-06. Epub 2006 Nov 1.
8
Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion.爱泼斯坦-巴尔病毒gp42经过翻译后修饰,产生可溶性gp42,介导HLA II类免疫逃逸。
J Virol. 2005 Jan;79(2):841-52. doi: 10.1128/JVI.79.2.841-852.2005.
9
Mycobacterium bovis BCG urease attenuates major histocompatibility complex class II trafficking to the macrophage cell surface.牛分枝杆菌卡介苗脲酶减弱主要组织相容性复合体II类分子向巨噬细胞表面的转运。
Infect Immun. 2004 Jul;72(7):4200-9. doi: 10.1128/IAI.72.7.4200-4209.2004.
10
Impact of human cytomegalovirus latent infection on myeloid progenitor cell gene expression.人巨细胞病毒潜伏感染对髓系祖细胞基因表达的影响。
J Virol. 2004 Apr;78(8):4054-62. doi: 10.1128/jvi.78.8.4054-4062.2004.